Skip to main content
SpringerLink
Log in

Capedtabine in Advanced Gastric or Oesophagogastric Cancer

A Viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe

  • Adis Drug Profiles
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Evans TR, Pentheroudakis G, Paul J, et al. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable esophago-gastric adenocarcinoma. Ann Oncol 2002; 13: 1469–78

    Article  PubMed  CAS  Google Scholar 

  2. Nishina T, Hyodo I, Miyaike J, et al. The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of clinical response to 5′-deoxy-5-flurouridine. Eur J Cancer 2002; 40: 1566–71

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of California, Irvine, Orange, California, USA

    Sai-Hong Ignatius Ou & Randall F. Holcombe

Authors
  1. Sai-Hong Ignatius Ou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Randall F. Holcombe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ou, SH.I., Holcombe, R.F. Capedtabine in Advanced Gastric or Oesophagogastric Cancer. Drugs 67, 611 (2007). https://doi.org/10.2165/00003495-200767040-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767040-00011

Search

Navigation